OctoPlus N.V. has signed a pharmaceutical development contract with Galapagos N.V. OctoPlus will manufacture clinical trial material for Galapagos' Phase II study of Nanocort, a liposome formulation of prednisolone.
OctoPlus, Galapagos Sign Manufacturing Contract
Published February 12, 2009
Related Searches:
Industry News
•
blog comments powered by Disqus
